COMP <GO>
MDXG vs MRK // ENTERPRISE SCALE & MARKET CAP
MiMedx Group Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: MDXG 8
— MRK 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $3.88 (-2.27%) • MKT CAP: $579.3M
market-cap
$579.3M
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDXG VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDXG | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.60% | 74.80% | +7.80 | MDXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 47.20% | 20.70% | +26.50 | MDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.7x | 15.3x | -8.60 | MDXG | /valuation <GO> |
| Free Cash Flow Yield | 12.77% | 3.42% | +9.35 | MDXG | /fcf-yield <GO> |
| Operating Margin | 15.30% | 34.30% | -19.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 28.10% | -16.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 1.30% | +18.70 | MDXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.45 | 5.19 | +1.26 | MDXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | MDXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 51.7 | -14.00 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.0x | 18.4x | -8.40 | MDXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $579.3M | $361.02B | -$360.44B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDXG REV | MRK REV | MDXG GROSS % | MRK GROSS % | MDXG FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $418.6M | $65.01B | 82.6% | 74.8% | $74.0M | $12.36B |
| FY 2024 | $348.9M | $64.17B | 82.8% | 76.3% | $66.2M | $18.10B |
| FY 2023 | $321.5M | $60.12B | — | — | $26.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDXG // BETA —
MRK // BETA 0.92